Charlie Bramlett, PhD

Charlie is a Technology Licensing Manager at the USC Stevens Center for Innovation.

He is a scientist with 10 years of experience in stem cells, cancer, and genetics research. Prior to joining the USC Stevens Center, Charlie was a Scientist at Vertex Pharmaceuticals, where he worked on the Hematology Research Team responsible for CASGEVY, the world’s first internationally approved CRISPR/Cas9 based gene-edited therapy. Charlie completed a fellowship at Foresite Capital, where he supported due diligence for prospective investment and assessed market landscapes for therapeutic areas of interest. His PhD thesis work was supported by the NIH F31 fellowship, enabling novel approaches of genetic barcoding and single cell genomics to understand the cellular and molecular heterogeneity of stem cells during leukemiagenesis.

He earned a BS in Genetics and Genomics from the University of California, Davis, an MS in Stem Cell Biology and Regenerative Medicine, and a PhD in Development, Stem Cells, and Regenerative Medicine from the University of Southern California.